Stay updated on Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial
Sign up to get notified when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.

Latest updates to the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page
- Check6 days agoChange DetectedThe ClinicalTrials.gov record for the adaptive-dosing melanoma study is displayed, including its eligibility criteria, locations, treatment plan, outcomes, and record history.SummaryDifference50%

- Check13 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoChange DetectedA site-wide notice was added explaining NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check27 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error page.SummaryDifference0.2%

- Check34 days agoChange DetectedThe revision label in the site footer changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check55 days agoChange DetectedThe study page now shows a 403 Forbidden error page instead of the study details, indicating the record is temporarily inaccessible. This change reflects an access issue rather than updated trial information.SummaryDifference17%

Stay in the know with updates to Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.